Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Health-economic analyses from the DEVOTE trial: cost per QALY for insulin degludec vs glargine U100, payer coverage gaps, list-price vs net-price realities, and how to frame the value calculation for individual patients with T2D and cardiovascular risk.
Read clinical reviewDeep-dive into post-trial follow-up from DEVOTE: durability of degludec's CV safety signal, long-term hypoglycemia patterns, and what emerged after the key 2017 NEJM publication.
Read clinical reviewA deep dive into the DEVOTE trial's primary and secondary endpoint results, effect sizes, confidence intervals, subgroup analyses, and hypoglycemia outcomes for insulin degludec vs glargine U100 in type 2 diabetes.
Read clinical reviewDeep-dive into the DEVOTE trial's pre-specified and post-hoc subgroup analyses comparing insulin degludec vs glargine U100 across age, sex, BMI, race, and baseline biomarkers in T2D patients with cardiovascular risk.
Read clinical reviewA plain-English breakdown of the DEVOTE trial: the clinical question, enrollment criteria, methodology, full results, limitations, and what insulin degludec's CV non-inferiority and lower nocturnal hypoglycemia mean for practice today.
Read clinical reviewA deep-dive into the methodological limitations, enrollment biases, statistical caveats, and conflict-of-interest concerns surrounding the DEVOTE cardiovascular outcomes trial of insulin degludec vs glargine in type 2 diabetes.
Read clinical reviewA deep-dive into the DEVOTE trial's randomization, blinding, endpoint adjudication, statistical framework, and comparator logic for insulin degludec vs glargine U100 in high-CV-risk type 2 diabetes.
Read clinical review